Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity
Open Access
- 14 April 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8), 2153-2165
- https://doi.org/10.1158/0008-5472.can-15-1965
Abstract
The field of immunotherapy for solid tumors, such as prostate cancer, has been recently focusing on therapies that can counter tumor-mediated immunosuppression. Precise quantification and characterization of the immune infiltrates in tumors is crucial to improve treatment efficacy. Natural killer (NK) cells, major components of the antitumor immune system, have never been isolated from prostate tumors, despite their suspected role in disease progression. Here, we examined the frequency, phenotype, and functions of NK cells infiltrating control and tumor prostate tissues. NK cell infiltrates in prostate tissues were mainly CD56 (NCAM1)-positive and displayed an unexpected immature, but activated, phenotype with low or no cytotoxic potential. Furthermore, we show that TGFβ1 (TGFB1) is highly secreted into the prostate environment and partly mediates the immunosuppressive effects on NK cells. In addition to this basal level of immunotolerance to NK cells, the prostate environment became further resistant to NK cell–mediated immunity upon cancer cell infiltration. Coculture experiments revealed that prostate cancer cells induced the expression of inhibitory receptor (ILT2/LILRB1) and downregulated the expression of activating receptors NKp46 (NCR1), NKG2D (KLRK1), and CD16 (FCGR3) by NK cells, thus preventing their recognition of tumor cells. Notably, blood levels of NKp46 were also decreased in prostate cancer patients and were inversely correlated with levels of prostate-specific antigen, the main prognostic factor in prostate cancer. Our study shows that a strong immunosuppressive environment impairs NK cell function at multiple levels in prostate cancer and provides a rationale for the design of therapies that restore NK cell efficiency in the prostate tumor microenvironment. Cancer Res; 76(8); 1–13. ©2016 AACR.Keywords
Other Versions
This publication has 47 references indexed in Scilit:
- Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasisJCI Insight, 2013
- Prostate Cancer ImmunotherapyClinical Cancer Research, 2011
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumorsNature Medicine, 2011
- TGF‐β affects development and differentiation of human natural killer cell subsetsEuropean Journal of Immunology, 2010
- Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for ImmunoeditingClinical Cancer Research, 2009
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg SkewingClinical Cancer Research, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- TGFβ promotes conversion of CD16+peripheral blood NK cells into CD16−NK cells with similarities to decidual NK cellsProceedings of the National Academy of Sciences of the United States of America, 2007